Menu Search
Equities

Swedencare AB (publ)

SECARE:STO

Swedencare AB (publ)

Actions
  • Price (SEK)44.70
  • Today's Change-0.40 / -0.89%
  • Shares traded92.36k
  • 1 Year change-9.40%
  • Beta0.9655
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Swedencare AB (publ) had net income fall -37.96% from 94.45m to 58.60m despite a 27.48% increase in revenues from 1.83bn to 2.34bn.
Gross margin56.76%
Net profit margin3.08%
Operating margin9.08%
Return on assets0.75%
Return on equity0.98%
Return on investment0.77%
More ▼

Cash flow in SEKView more

In 2023, Swedencare AB (publ) did not generate a significant amount of cash. However, the company earned 444.00m from its operations for a Cash Flow Margin of 18.99%. In addition the company used 176.40m on investing activities and also paid 271.60m in financing cash flows.
Cash flow per share2.46
Price/Cash flow per share18.34
Book value per share48.39
Tangible book value per share-4.05
More ▼

Balance sheet in SEKView more

Swedencare AB (publ) has a Debt to Total Capital ratio of 17.26%, a lower figure than the previous year's 22.96%.
Current ratio3.03
Quick ratio1.67
Total debt/total equity0.2086
Total debt/total capital0.1726
More ▼

Growth rates in SEK

Year on year, growth in dividends per share increased 4.55% while earnings per share excluding extraordinary items fell by -100.00%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
Div yield(5 year avg)0.29%
Div growth rate (5 year)--
Payout ratio (TTM)47.91%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		204.18
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.